C&L: Peacock tapped to run Alba

Dr. Blake Paterson has been replaced as chief executive of Alba Therapeutics. Bruce Peacock, a venture partner with SV Life Sciences Advisors LLC, will take over for Paterson, who founded the company.

Dr. Iain Chessell, former worldwide head of pain research at GlaxoSmithKline, has commenced work as CEO of NeuroDiscovery.

DiaMedica has appointed Thomas Wellner to the board of directors, and announced the resignation of Dr. Albert Friesen from board. Rick Pauls was named chairman, interim president and CEO following the resignation of Dr. Karl-Gunnar Hidinger as president.

Cylex has named Brad Stewart president of the company.

PPD chief medical officer Dr. Paul Covington is retiring from the clinical research organization in June.

Stiefel Laboratories has promoted Dr. Gavin Corcoran to the newly created position of chief scientific officer.

The Immune Tolerance Institute has added Aaron Kantor, Ph.D. as chief scientific officer.

SciClone Pharmaceuticals announced that Executive Vice President and Chief Financial Officer Richard Waldron has resigned to pursue another professional opportunity.

Caliper Life Sciences has named Peter McAree as senior vice president and chief financial officer.

Nucryst Pharmaceuticals said that Eliot Lurier plans to step down as chief financial officer.

John Librie has been named senior vice president of sales and marketing at Acorda Therapeutics.

NuGEN Technologies has hired Dr. Douglas Amorese to serve as the company's vice president of research and development.

Adventrx Pharmaceuticals has appointed Jose Hechavarria to the new position of vice president of manufacturing. 

Mark Day has been named senior director of cognitive neuroscience at PsychoGenics.

BrainStorm Cell Therapeutics has appointed former U.S. Assistant Surgeon General, Rear Admiral Roscoe Moore, Jr. (USPHS, Ret) to the company's advisory board.

Egenix has named Daniel Petrylak, MD  chairman of the company's scientific advisory board.

Asterand has named Dr. Peter Coggins as a non-executive director.

EntreMed announced the retirement of Ronald Cape, Ph.D. as director.

IDM Pharma has named Gregory Tibbitts to its board of directors.

Senomyx has appointed Roger Billingsley, Ph.D., as a director and a member of the corporate governance and nominating committee. Senomyx also announced that Kent Snyder has been named to assume the role of chairman of the board.

 

Suggested Articles

Vital strategies for steriles development to ensure more flexibility within drug development.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.